Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia

Lancet. 2017 Nov 25;390(10110):2343-2345. doi: 10.1016/S0140-6736(17)32894-5.

¹ Department of Medical Oncology, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital, Imperial College London, London W6 8RF, UK; Cancer Immunology Unit, University College London Cancer Institute, London, UK.
² Department of Histopathology, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital, Imperial College London, London W6 8RF, UK.
³ Department of Medical Oncology, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital, Imperial College London, London W6 8RF, UK.
⁴ Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
⁵ Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
⁶ Department of Cellular Pathology, University College London Hospital, London, UK.
⁷ Cancer Immunology Unit, University College London Cancer Institute, London, UK.
⁸ Department of Medical Oncology, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital, Imperial College London, London W6 8RF, UK. Electronic address: m.seckl@imperial.ac.uk.

No abstract available

Publication types